Tozorakimab shows significant benefit in two major COPD trials
30th March 2026 Uncategorised 0
Phase 3 studies report meaningful reductions in exacerbations across broad patient groups

More: Tozorakimab shows significant benefit in two major COPD trials
Source: News
